The study emphasizes the influence of Rademikibart on blood -eo -eosinophil numbers in asthma

A new analysis suggests that, unlike Dupilumab, Rademikibart does not cause eosinophilic increase in patients with asthma and highlights a possible distinction in the interaction of the 2 biologics with interleukin (IL) -4Rα.¹

These results were presented in a poster meeting at the International Conference of the American Thoracic Society (ATS) in San Francisco. The poster for this new research had the title “Effect of Rademikbart on Blood-Eosinophil numbers in patients with asthma: Is there an IL-4Rα class effect?” And it was written by investigators such as Raúl Collazo, PhD, Vice President and Global Head of Medical Affairs for Connect Biopharma.

The subgroup of respiratory disorders, which are referred to as inflammatory respiratory diseases of type 2 (T2), is known to be characterized by persistent inflammation, which were associated with T2-cytokines such as IL-4, IL-5 and IL-13. It is also known that such conditions usually occur with increased fractional exhalation nitrogen oxide (feno), increased serum -mirrors and high numbers of eosinophils (EOS).

Collazo and Coautor emphasized that the dupilumab treatment, which was developed to inhibit the IL-4 receptor Alpha (IL-4RRO), was previously associated with cases of over height high altitude. They added that this was found in certain patients who started their therapy with Eosinophil levels of more than 500 cells/μl.

The next generation's IL-4Rα antagonist, which is known as a wheel miobart, has previously continued several remarkable and persistent lung function improvements in the first week and the 24-week brand. Collazo et al. Attempting to evaluate whether eosinophilia is a class effect that is common in the IL-4R blockade, and consider safety data from this phase-2 analysis and in which medium heavy to severe with uncontrolled asthma.

For this clinical phase 2B study, 322 people were recruited in which a global, randomized, placebo-controlled design was involved. At 79 locations, the investigation team received the participants in a ratio of 1: 1: 1 to either get a base of 2 weeks (Q2W; n = 106), Rademikibart 300 mg Q2W with a charging dose of 600 mg (n = 108) or a placebo (n = 108).

The incidence of eosinophilia (defined as EOS> 1500 -cells/μl) as well as hypereosinophilia (EOS> 3000 cells/μl) was assessed by Collazo and colleagues, over the entire study population and in an sub -group with increased basic lines -Eosinophils (> 500 cells/μl). These results refer to the higher 300 mg Q2W dosage group.

In the 24-week brand, those who were treated with cycling bart saw a greater reduction in the eosinophils from the time of the base line compared to those in the placebo group.¹ The percentage changes were as follows:

Week 1: -4.6% for those on Rademikibart compared to -0.3% for placebo

Week 4: -11.9% compared to -1.7%

Week 24: -38.5% compared to -10.7%

When evaluating subjects with basic eosinophilic mirrors over 500 cells/μl, it was found that 10% of those on Rademikbart have a peak -eo -eosinophil number of more than 1500 cells/μl during the course of the analysis. This was compared to 18.8% in the placebo cohort.

In a remarkable finding, Collazo and Co authors emphasized that no participants who were included in the study in the Rademikbart (0%) reached the threshold for overdemenosinophilia (> 3000 cells/μl). Overall, they also came to the conclusion that the security profile of Rademikbart was cheap and aligned with previous data.

While earlier studies on DuPilumab have shown that the medicine was associated with the medicine and hyperosinophilia in 13% in 42% of people with eosinophilia, the present analysis suggests that the changes in the Eosinophils in the placo -arms are consistent.

This would indicate that the differences observed by the examination team are likely to be attributed to the specific medicine to be assessed, which supports the idea that cycling beard does not have the same eosinophilic related effects as duPilumab.

Further data at ATS 2025 can be found in our latest reporting on the conference.

References

1. Collazo R, Wechsler M, Quart B. (Posterboard # P1515) Effect of Rademikibart on the numbers of blood-eosinophils in patients with asthma: Is there an IL-4Rα class effect? Abstract presented by the International Conference 2025 of the American Thoracic Society (ATS) in San Francisco, CA, from May 18, 2025.